<DOC>
	<DOCNO>NCT02788123</DOCNO>
	<brief_summary>The main purpose study evaluate clinical efficacy bismuth tripotassium dicitrate ( De-Nol ) combination pantoprazole versus pantoprazole monotherapy subject NSAID-induced gastropathy 14±2 day treatment .</brief_summary>
	<brief_title>A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate ( De-Nol ) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs ( NSAID ) -Induced Gastropathy</brief_title>
	<detailed_description>This study screen period ( 3±2 day duration ) . Randomization hold stratum ( H. pylori-positive H. pylori-negative ) Visit 1 . Treatment period consist 2 visit : Visit 2 ( 14±2 day Visit 1 ) subject completely heal ulcer ( ) erosion control esophagogastroduodenoscopy ( EGDS ) Visit 3 ( 28±2 day Visit 1 ) subject heal ulcer erosion control EGDS Visit 2 . The period follow-up safety assessment last 1 week end study treatment</detailed_description>
	<mesh_term>Stomach Diseases</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Bismuth tripotassium dicitrate</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Verified diagnosis NSAIDinduced gastropathy : Presence gastric ulcer ( ) and/or erosion ( modify Lanza score great equal 5 ) base EGDS finding screen ; NSAIDs administration within 7 day screen . Negative pregnancy test screen Visit 1 ( female use test strip detect chorionic gonadotropin urine ) , Subjects ' consent use reliable contraception method start screen throughout whole study 1 week termination . Severe complication NSAIDgastropathy ( bleeding , perforation , etc . ) The subject require concomitant therapy use drug specify `` Forbidden concomitant therapy '' . Ulcerative esophagitis grade C high accord LosAngeles classification . Expressed hepatic renal impairment . Any esophageal gastric surgery make subject ineligible study participation . Abuse psychoactive substance include alcohol may interfere subject 's participation fulfillment protocol requirement . Participation clinical study within 30 day prior Screening Visit . Administration bismuth product less 2 month prior screen . Administration PPIs histamine Н2receptor antagonists less 2 week prior screen . Hypersensitivity component study drug contraindication . Pregnancy lactation . Inability perform followup EGDS 2 and/or 4 week study . Any condition concomitant disease laboratory parameter abnormalities render subject ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>De-Nol</keyword>
	<keyword>NSAID-induced gastropathy</keyword>
	<keyword>Pantoprazole</keyword>
	<keyword>Bismuth tripotassium dicitrate</keyword>
	<keyword>Russia</keyword>
</DOC>